Topical Glaucoma Therapy as a Risk Factor for Nasolacrimal Duct Obstruction

American Journal of Ophthalmology

Volumn 145, Issue 1, 2008, Pages

  Seider, Nir ^a   Miller, Benjamin ^a,b   Beiran, Itzchak ^a,b  

^a RAMBAM MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGLAUCOMA AGENT; BRIMONIDINE; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; PILOCARPINE; PROSTAGLANDIN DERIVATIVE; TIMOLOL;

ADULT; AGED; ARTICLE; CATARACT EXTRACTION; CHRONIC DRUG ADMINISTRATION; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HUMAN; LACRIMAL DUCT OCCLUSION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OPEN ANGLE GLAUCOMA; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 37249087174     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2007.07.033     Document Type: Article

References (18)

1. Tanenbaum M., and McCord C.D. Lacrimal drainage system. In: Tasman W. (Ed). Duane's clinical ophthalmology Vol. 4 (2001), Lippincott, Williams & Wilkins, Philadelphia, Pennsylvania 1-34 Revised ed.
2. Hirschbein M.J., and Stasior G.O. Lacrimal system. In: Chen W.P. (Ed). Oculoplastic surgery-the essentials. 1st ed. (2001), Thieme Medical Publishers, Inc, New York, New York 263-288
3. Linberg J.V., and McCormick S.A. Primary acquired nasolacrimal duct obstruction. A clinicopathologic report and biopsy technique. Ophthalmology 93 (1986) 1055-1063
4. Tucker N., Chow D., Stockl F., Codere F., and Burnier M. Clinically suspected primary acquired nasolacrimal duct obstruction: clinicopathologic review of 150 patients. Ophthalmology 104 (1997) 1882-1886
5. Mauriello Jr. J.A., Palydowycz S., and DeLuca J. Clinicopathologic study of lacrimal sac and nasal mucosa in 44 patients with complete acquired nasolacrimal duct obstruction. Ophthal Plast Reconstr Surg 8 (1992) 13-21
6. Lee-Wing M.W., and Ashenhurst M.E. Clinicopathologic analysis of 166 patients with primary acquired nasolacrimal duct obstruction. Ophthalmology 108 (2001) 2038-2040
7. DeAngelis D., Hurwitz J., Oestreicher J., and Howarth D. The pathogenesis and treatment of lacrimal obstruction: the value of lacrimal sac and bone analysis. Orbit 20 (2001) 163-172
8. Paulsen F.P., Thale A.B., Maune S., and Tillmann B.N. New insights into the pathophysiology of primary acquired dacryostenosis. Ophthalmology 108 (2001) 2329-2336
9. McNab A.A. Lacrimal canalicular obstruction associated with topical ocular medication. Aust N Z J Ophthalmol 26 (1998) 219-223
10. Zolli C.L., and Shannon G.M. Dacryocystorhinostomy: a review of 119 cases. Ophthalmic Surg 13 (1982) 905-910
11. Lee A.J., Mitchell P., Rochtchina E., and Healey P.R. Female reproductive factors and open-angle glaucoma: the Blue Mountains Eye Study. Br J Ophthalmol 87 (2003) 1324-1328
12. Hulsman C.A., Westendorp I.C., Ramrattan R.S., et al. Is open-angle glaucoma associated with early menopause?. The Rotterdam Study. Am J Epidemiol 154 (2001) 138-144
13. Nirmalan P.K., Katz J., Robin A.L., et al. Female reproductive factors and eye disease in a rural South Indian population: the Aravind Comprehensive Eye Survey. Invest Ophthalmol Vis Sci 45 (2004) 4273-4276
14. Janssen A.G., Mansour K., Bos J.J., and Castelijns J.A. Diameter of the bony lacrimal canal: normal values and values related to nasolacrimal duct obstruction: assessment with CT. AJNR Am J Neuroradiol 22 (2001) 845-850
15. Groessl S.A., Sires B.S., and Lemke B.N. An anatomical basis for primary acquired nasolacrimal duct obstruction. Arch Ophthalmol 115 (1997) 71-74
16. Shaffer R.N., and Ridgway W.L. Furmethide iodide in the production of dacryostenosis. Am J Ophthalmol 34 (1951) 718-720
17. Spaeth G.L. Nasolacrimal duct obstruction caused by topical epinephrine. Arch Ophthalmol 77 (1967) 355-357
18. Stahl U., Francis I.C., and Stapleton F. Prospective controlled study of vapor pressure tear osmolality and tear meniscus height in nasolacrimal duct obstruction. Am J Ophthalmol 141 (2006) 1051-1056